Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib + trametinib in pediatric refractory BRAF V600-mutant solid tumors
jRCTs011220017Completed
- Sponsor
- crowdfunding
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dabrafenib + trametinib and trametinib in Nonhematologic neoplasms, brain neoplasm and histiocytosis, sponsored by crowdfunding. Primary endpoint: Confirmed objective response rate by RECIST v1.1 up to Week 24. Started May 2023; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
Nonhematologic neoplasmsbrain neoplasmhistiocytosis
Beyond the preview
Go deeper on jRCTs011220017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011220017.